Redx Pharma (LON:REDX) Stock Passes Below Fifty Day Moving Average of $14.29

Redx Pharma Plc (LON:REDX) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 14.29 ($0.18) and traded as low as GBX 11.42 ($0.14). Redx Pharma shares last traded at GBX 15 ($0.19), with a volume of 1,420,135 shares changing hands.

Redx Pharma Stock Up 31.6 %

The company has a debt-to-equity ratio of 527.00, a current ratio of 1.11 and a quick ratio of 1.93. The company has a 50-day moving average of GBX 14.29 and a two-hundred day moving average of GBX 17.45. The company has a market capitalization of £58.35 million, a PE ratio of -150.00 and a beta of -0.53.

Insider Activity

In other news, insider Lisa Anson acquired 115,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were purchased at an average cost of GBX 9 ($0.11) per share, for a total transaction of £10,350 ($13,129.52). Insiders own 18.35% of the company’s stock.

Redx Pharma Company Profile

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.